Cowen and Company’s Amicus Therapeutics FOLD Stock Holding History

Cowen and Company’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,001	Closed	-$159K	–	614
2022 Q4	$159K	Buy	+13,001	New	+$146K	0.02%	186
2022 Q1	–	Sell	-41,582	Closed	-$480K	–	648
2021 Q4	$480K	Sell	41,582 -25,918	-38%	-$289K	0.04%	232
2021 Q3	$645K	Buy	67,500 +46,500	+221%	+$476K	0.03%	175
2021 Q2	$202K	Buy	21,000 +11,000	+110%	+$107K	0.01%	279
2021 Q1	$99K	Buy	+10,000	New	+$155K	0.01%	324

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cowen and Company's FOLD Position: Q1 2023 in Review

Cowen and Company sold out of Amicus Therapeutics (FOLD) in Q1 2023, closing a stake of 13,001 shares — an estimated $159K sold.

Cowen and Company first reported a position in FOLD in Q1 2021 and held it in 5 quarters. The position peaked at $645K in Q3 2021. 226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

Cowen and Company reported no remaining Amicus Therapeutics position as of Q1 2023 after selling out during the quarter.
Cowen and Company sold 13,001 Amicus Therapeutics shares in Q1 2023, an estimated $159K.
Cowen and Company first reported a position in Amicus Therapeutics in Q1 2021 and held it in 5 quarters.
Cowen and Company's Amicus Therapeutics position peaked at $645K in Q3 2021.
226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.